Form 8-K - Current report:
SEC Accession No. 0001367644-25-000183
Filing Date
2025-09-05
Accepted
2025-09-05 17:23:20
Documents
20
Period of Report
2025-09-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20250902.htm   iXBRL 8-K 30165
2 EX-10.1 cyfendusmod.htm EX-10.1 9187
3 EX-99.1 a09022025cyfenduspressrele.htm EX-99.1 16294
8 cyfendusmod001.jpg GRAPHIC 258636
9 cyfendusmod002.jpg GRAPHIC 87407
10 cyfendusmod003.jpg GRAPHIC 177446
11 cyfendusmod004.jpg GRAPHIC 67808
12 image2a.jpg GRAPHIC 7489
  Complete submission text file 0001367644-25-000183.txt   1039097

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20250902.xsd EX-101.SCH 2059
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ebs-20250902_def.xml EX-101.DEF 15289
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20250902_lab.xml EX-101.LAB 26963
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20250902_pre.xml EX-101.PRE 15991
22 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20250902_htm.xml XML 2722
Mailing Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879
Business Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 251297550
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)